Esophageal cancer
Conditions
Interventions
Experimental group:Photon radiotherapy combined with carbon ion radiotherapy
Sponsors
Gansu Wuwei Tumor Hospital Heavy Ion Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.The pathology confirmed squamous or adenocarcinoma; 2.AJCC 2017 8th Edition CT1-4 any N M0 (Table 5.1); 3.Renal function, liver function and bone marrow function were basically normal (serum creatinine 9.5 g/dL. White blood cell count,>=3000 / ml; Platelet count >= 100,000 /mL); 7.Aged 18 to 80 years; 8.Good physical condition, ECOG (Eastern United States Collaborative Oncology Group) =6 months; 10.Prior to radiotherapy, the patient or his/her legal representative has signed the informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with esophageal tracheal fistula or who have been judged by physicians to be at high risk of esophageal tracheal fistula: 2.Weight loss of more than 20% within six months; 3.Pregnancy (confirmed by serum or urine ß-HCG test) or lactation period; 4.Drug or alcohol abuse; 5.AIDS patients; 6.Concomitant with uncontrolled systemic, pulmonary or heart disease; 7.Concomitant serious comorbidities, including uncontrolled comorbidities (pulmonary insufficiency, cardiovascular, lung, liver, kidney, diabetes, etc.), addiction, and/or mental illness that prevent the trial regimen from proceeding smoothly; 8.Implant pacemaker or other metal prosthesis enough to affect radiotherapy; 9.Patients with poor compliance, including the possibility of failing to complete the treatment plan or receiving the required follow-up and testing; 10.Previous experience with other malignant tumors (except non-malignant melanoma skin cancer or non-invasive cervical cancer); 11.Simultaneously receiving systemic immunotherapy or corticosteroid therapy; 12.Serum creatinine clearance rate < 30ml/ min; 13.Contraindications to radiotherapy; 14.Participated in other drug clinical trials within 30 days prior to inclusion in this study; 15.Incapacity or limited capacity for civil conduct; 16.Any medical history that, in the investigator's judgment, may interfere with trial results or increase patient risk; 17.Any circumstances in which the physician deems it inappropriate to participate in the trial; 18.Distant metastasis to solid organs; 19.Received radiation therapy for esophageal cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local control rate of tumor;Tumor response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median progression-free survival;Median survival;Distant metastasis rate; | — |
Countries
China
Contacts
Public ContactZhang Yanshan
Gansu Wuwei Tumor Hospital Heavy Ion Center
Outcome results
None listed